Skip to main content
Log in

Will clinical trial data disclosure reduce incentives to develop new uses of drugs?

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Hypothetical simplified clinical trial data at different disclosure levels, modeled loosely on interferon-a2b.

References

  1. European Medicines Agency. Publication of clinical reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002181.jsp&mid=WC0b01ac058004d5c1 (2 October 2014).

  2. The Council of the European Union. Council adopts new rules on clinical trials. http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/142181.pdf (14 April 2014).

  3. US Food and Drug Administration. Fed. Reg. 78, 33421–33423 (2013).

  4. Mello, M.M. et al. N. Engl. J. Med. 369, 1651–1658 (2013).

    Article  CAS  Google Scholar 

  5. Roin, B.N. Social Science Research Network http://dx.doi.org/10.2139/ssrn.2337821 (October 10, 2013)

    Google Scholar 

  6. Doshi, P. Br. Med. J. 347, f6754 (2013).

    Article  Google Scholar 

  7. DiMasi, J.A., Reichert, J.M., Feldman, L. & Malins, A. Clin. Pharmacol. Ther. 94, 329–335 (2013).

    Article  CAS  Google Scholar 

  8. MEHL/Biophile Int'l Corp. v. Milgraum, 192 F.3d 1362 (1999).

  9. T128/82 (Pyrrolidin-Derivate) Case T 128/82 - Hoffman-La Roche/Pyrrolidine-derivatives O.J. EPO 1984, 164 (Jan. 12, 1984)

  10. G2/08 (Dosage regime/Abbott Respiratory) Case G 2/08 - Dosage regime/Abbott Respiratory 2010 O.J. EPO 456 (Feb. 19, 2010)

  11. Torjesen, I. Br. Med. J. 348, g3432 (2014).

    Article  Google Scholar 

  12. EU Commission, COM/2013/0813 final - 2013/0402 (COD), Proposal for a Directive of the European Parliament and of the Council on the protection of undisclosed know-how and business information (trade secrets) against their unlawful acquisition, use and disclosure. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52013PC0813 (Nov. 28, 2013)

  13. European Federation of Pharmaceutical Industries and Associations. EFPIA welcomes the Commission's Proposal on the protection of undisclosed know-how and business information (“Trade Secrets”). http://www.efpia.eu/mediaroom/129/44/EFPIA-welcomes-the-Commission-39-s-Proposal-on-the-protection-of-undisclosed-know-how-and-business-information-quot-Trade-Secrets-quot (28 November 2013).

Download references

Acknowledgements

The authors wish to thank I. Glenn Cohen and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School for support and advice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to W Nicholson Price II.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Price, W., Minssen, T. Will clinical trial data disclosure reduce incentives to develop new uses of drugs?. Nat Biotechnol 33, 685–686 (2015). https://doi.org/10.1038/nbt.3243

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3243

  • Springer Nature America, Inc.

This article is cited by

Navigation